MichaelSGordonMD

Oncology • Scottsdale, AZ

Genitourinary Oncology, Gynecologic Cancer, Hematologic Oncology, Melanoma

Chief Medical Officer at HonorHealth Research Institute Medical Director, Oncology Clinical Trials at HonorHealth Research Institute

Join to view full profile

Dr. Gordon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gordon's full profile

Already have an account?

Office
10510 N 92nd Street Suite 200
Scottsdale, AZ 85258
Phone+1 480-323-1350

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
University of ChicagoResidency, Internal Medicine, 1985 - 1988
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1985
Sophie Davis School for Biomedical Education at CCNYBS, Biomedical Science, 1979 - 1983

Certifications & Licensure

AZ State Medical License 2000 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
Unknown status
Phase 1
Safety and Efficacy Study of Glufosfamide in Ovarian Cancer Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors Start of enrollment: 2008 Jan 01
Terminated
Phase 1
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 1
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors Start of enrollment: 2014 Apr 01
Terminated
Phase 1, Phase 2
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies Start of enrollment: 2017 Dec 01
Completed
Phase 1
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Start of enrollment: 2019 Apr 01
Recruiting
Phase 1
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC Start of enrollment: 2019 Jul 02
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastat...
Breelyn A Wilky, Gary K Schwartz, Michael S Gordon, Anthony B El-Khoueiry, Andrea J Bullock
Journal of Clinical Oncology. 2025-01-27
11 citations
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.
Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Joseph E Grossman
Nature Medicine. 2024-09-01
1 citations
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+...
Alice N Weaver, Wade T Iams, Jong Chul Park, Monica Mita, Udo Holtick
Molecular Carcinogenesis. 2024-08-01

Journal Articles

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung Carcinoma
Beth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer
E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain Metastases
Mitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs

Lectures

A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) w...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018

Press Mentions

TGen Partners with a Phoenix-Area Hospital System to Test COVID-19 TreatmentMay 5th, 2020
Advances in Cancer TreatmentSeptember 29th, 2017
Arizona Cancer Center Faces Crowded Cancer-Care MarketSeptember 2nd, 2015

Professional Memberships

Industry Relationships

co-Founder, Caremission